Brief: New Secondary Analysis Of Phase 3 Data Demonstrates That Inpefa (Sotagliflozin) Benefited Heart Failure Patients Regardless Of Diabetes Duration
03/09/2024 13:46
Sept 3 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O :
* NEW SECONDARY ANALYSIS OF PHASE 3 DATA DEMONSTRATES THAT
INPEFA®
(SOTAGLIFLOZIN) BENEFITED HEART FAILURE PATIENTS REGARDLESS OF
DIABETES DURATION
Source text for Eikon: ID:nGNX7srjSx
Further company coverage: LXRX.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview